TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.

William G Wierda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.